Bonesupport Q2 revenue rose 37% to SEK 278.5 million, with U.S. sales up 44%. The company swung to an operating profit and raised its full-year guidance to SEK 1.05-1.10 billion.
Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality, moderate sentiment.
Bonesupport Holding AB reported second-quarter results on July 16, showing revenue growth that accelerated from the prior quarter. The company posted quarterly revenue of SEK 278.5 million, up 37% year-over-year, compared with 27% growth in Q1.
The orthobiologics company, which sells a bone-graft substitute called Cerament, said the U.S. market drove the acceleration. U.S. revenue rose 44% to SEK 183.2 million, accounting for roughly two-thirds of total sales. International revenue grew 24% to SEK 95.3 million.
Gross margin widened to 87.5% from 86.1% a year earlier, helped by higher production volumes and favorable product mix. The company swung to an operating profit of SEK 22.1 million from a loss of SEK 5.3 million in the same period last year.
Bonesupport raised its full-year revenue guidance to SEK 1.05 billion to SEK 1.10 billion, up from a prior range of SEK 980 million to SEK 1.03 billion. The new midpoint implies roughly 32% growth for the full year.
The company ended the quarter with SEK 382 million in cash and no debt.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.